Participate or Join us!
Integrating Pharmacogenetic information in existing health care
5th ESPT Congress 2019, Seville (16-18 october 2019)
PurposeImplementing and supporting Pharmacogenetics for the most important and actionable pharmacogenetic markers into clinical care and monitor uptake and experiences.
Countries• Austria • Belgium • Denmark • Finland • France • Germany • Greece • Hungary • Italy • Poland • Portugal • Slovenia • Spain • Sweden • Switserland • The Netherlands • Turkey • UK
5th ESPT Congress 2019Precision Medicine and Personalised HealthSeville 16-18 october 2019
To improve patient care in Europe by integrating Pharmacogenetic information in existing health care, personalising drug therapy.
Do you want do join the European Pharmacogenetics Implementation Consortium?
You can be an active participant from an organization or be a private partner.
Please fill in the contactform at the contactpage.
• IFCC: International Federation for Clinical Chemistry - www.ifcc.org.
• ESPT: European Society for Pharmacogenomics and Personal Therapy -
Implementing and supporting Pharmacogenetics for the most important and actionable pharmacogenetic markers into clinical care and monitor uptake and experiences.
Focus on Psychiatry, Internal Medicine, Cardiology and Oncology. Clinical implementation of Pharmacogenetics is important for improving drug therapy.
Pharmacogenetics is based on the understanding that all drugs are taken through several biochemical pathways to break them down after they are administered. The body needs to eliminate these drugs and does it by breaking them down through biochemical pathways.
An (extremely) fast or slow metabolism is in many cases caused by variations in CYP2D6 and CYP2C19 enzyme activity. Variations in the genes encoding these enzymes can result in increased or decreased enzyme activity.
Patients with a rapid metabolism may be unjustifiably accused of being unfaithful to therapy. They may not experience effects of the drug.
Patients with a slow metabolism often experience side effects, regardless of what medicine they are prescribed. In addition to side effects, they can also experience toxicity from the medicine used, which poses health risks.
CYP2D6 is responsible for metabolizing approximately 25% of medications.
To perform research in, and driving clinical implementation of Pharmacogenetics, as an important tool to improve drug therapy and current health care.
Numerous clinical studies have shown that inadequate neurotransmitter function has a profound influence on overall health and well-being. In fact, imbalances in certain neurotransmitters are associated with most of the prevalent symptoms and conditions seen in practitioners offices today including Mood disorders; depression, anxiety, fatigue, insomnia, loss of mental focus.
Identifying and managing neurotransmitter imbalances is facilitated with a noninvasive urinary test. Testing provides a tool to understand each patient’s specific neuroendocrine imbalances, which can be corrected with individualized treatment plans.
Personalised medicine has the potential to respond to, amongst others, the increasing burden of chronic disease and the complexity of co-morbidities and in doing so contribute to the sustainability of health and care systems.
This tutorial discusses how drugs are metabolised by Cytochrome P450 enzymes.